UK MHRA Pilot To Explore Benefits Of Standalone Inspections For Pharmacovigilance Service Providers
This article was originally published in SRA
Executive Summary
The UK Medicines and Healthcare Products Regulatory Agency has launched a pilot to ascertain whether the introduction of a new standalone program, under which it would inspect pharmacovigilance service providers, could cut inspection costs incurred by drug companies that use these third-party organizations and also save agency resources.